This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

If SpaceX CEO Musk was Biotech CEO, Rocket's 'Landing' Big Win

04/16/15 - 09:07 AM EDT

In which Musk learns how to put a happy spin on failure from biotech CEOs.

READ FULL POST

Cancer Immunotherapy Remains Hot as Aduro Biotech Doubles in Value On IPO Debut

04/15/15 - 11:35 AM EDT

Aduro Biotech shares doubled in value Wednesday following a successful initial public offering -- another sign that investor demand for cancer immunotherapy stocks remains strong.

READ FULL POST

Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched

04/07/15 - 08:02 AM EDT

The Loncar Cancer Immunotherapy Index (LCINDX) tracks biopharma companies developing (or already marketing) drugs which use the body's own immune system to target and kill cancer cells.

READ FULL POST

The Top-Performing Biotech Stock During a Sizzling First Quarter

04/01/15 - 09:30 AM EDT

That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.

READ FULL POST

Bankrupt Introgen Seeks Reincarnation IPO in Biotech Bubble

03/31/15 - 11:30 AM EDT

Will the biotech bubble support the comeback of Introgen Therapeutics, one of the sector's largest disasters?

READ FULL POST

Biotech Merger Monday Doesn't Squash Biotech Bubble Debate

03/30/15 - 10:43 AM EDT

Neither of the deals announced Monday are blockbusters or particularly transformative. Both buyers have specific needs and went after small targets for large prices.

READ FULL POST

PTC Therapeutics CEO Liquidates Stock Ownership in His Own Company

03/24/15 - 10:39 AM EDT

Biotech CEOs are supposed to be cheerleaders for their stock, so it's noteworthy when a CEO's pocketbook indicates otherwise.

READ FULL POST

Celgene's Crohn's Disease Drug Candidate Highlighted in NEJM

03/18/15 - 05:00 PM EDT

Celgene will be starting phase III studies of mongersen in Crohn's disease -- designed to lead to the drug's approval -- by the middle of the year.

READ FULL POST

Esperion CEO Twitter Trolls His Larger, Cholesterol-Lowering Rivals

03/17/15 - 10:26 AM EDT

When a biotech CEO diverts from safe, bland corporate tweets to engage in some clever competitive trolling, I stand and applaud.

READ FULL POST

CTI BioPharma Discloses More Data on Myelofibrosis Drug in SEC Filing

03/13/15 - 09:36 AM EDT

The cross-trial comparison between CTI BioPharma's pacritinib and Incyte's Jakafi looks worse than expected.

READ FULL POST

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs